BIDE PHARMATECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.34 CNY | -4.84% |
|
+3.50% | -34.52% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1.29B 178M | Sales 2025 * | 1.88B 260M | Capitalization | 3.19B 441M |
|---|---|---|---|---|---|
| Net income 2024 * | 249M 34.43M | Net income 2025 * | 293M 40.51M | EV / Sales 2024 * | 2.48 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.69 x |
| P/E ratio 2024 * |
13.3
x | P/E ratio 2025 * |
11.3
x | Employees | 617 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 30.18% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.84% | ||
| 1 week | +3.50% | ||
| Current month | +3.50% | ||
| 1 month | +4.58% | ||
| 3 months | -9.10% | ||
| 6 months | -44.82% | ||
| Current year | -34.52% |
1 week
36.11
38.77
1 month
30.9538.77
Current year
30.9556.00
1 year
30.9594.66
3 years
30.95114.05
5 years
30.95114.05
10 years
30.95114.05
| Managers | Title | Age | Since |
|---|---|---|---|
Lan Dai
CEO | Chief Executive Officer | 52 | 07-03-31 |
Mei Cai
CHM | Chairman | 39 | 12-04-30 |
Rong Hao Li
CTO | Chief Tech/Sci/R&D Officer | 41 | 08-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Meng
BRD | Director/Board Member | 58 | 23-10-12 |
Tao Li
BRD | Director/Board Member | 38 | 19-05-31 |
Lan Dai
CEO | Chief Executive Officer | 52 | 07-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 36.34 | -4.84% | 2,035,437 |
| 24-05-09 | 38.19 | +2.52% | 2,291,460 |
| 24-05-08 | 37.25 | +1.58% | 1,786,699 |
| 24-05-07 | 36.67 | +0.16% | 935,742 |
End-of-day quote Shanghai S.E., May 09, 2024
More quotes
Bide Pharmatech Co Ltd is a China-based company mainly engaged in pharmaceutical research and development. The Company's main businesses are the research, development, design, production and sales of drug molecular building blocks. The Company's main products are pharmaceutical molecular building blocks and scientific reagents. The Company's products are mainly used in drug target discovery, seed compound screening, lead compound discovery, synthesis and optimization. The Company conducts business in Asia Pacific, India, Europe, the United States and other regions.
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
36.34
CNY
Average target price
41
CNY
Spread / Average Target
+12.82%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.52% | 457M | |
| +22.44% | 44.96B | |
| +0.79% | 42.65B | |
| +46.00% | 41.85B | |
| -4.27% | 29.04B | |
| +10.87% | 26.08B | |
| -20.74% | 19.03B | |
| +5.24% | 12.75B | |
| +27.54% | 12.06B | |
| -3.89% | 11.75B |
- Stock Market
- Equities
- 688073 Stock
